Cannabidiol and neural correlates of threat anticipation in alcohol use disorder.

IF 3.3 3区医学 Q2 NEUROSCIENCES

Psychopharmacology Pub Date : 2026-09-01 DOI:10.1007/s00213-026-07148-y

Tristan Hurzeler, Warren Logge, Joshua Watt, Iain McGregor, Anastasia Suraev, Paul S Haber, Kirsten C Morley

{"title":"Cannabidiol and neural correlates of threat anticipation in alcohol use disorder.","authors":"Tristan Hurzeler, Warren Logge, Joshua Watt, Iain McGregor, Anastasia Suraev, Paul S Haber, Kirsten C Morley","doi":"10.1007/s00213-026-07148-y","DOIUrl":null,"url":null,"abstract":"Rationale: Cannabidiol (CBD) has previously been suggested to be an emerging pharmacotherapy for Alcohol Use Disorder (AUD), however, results from clinical studies remain mixed and potential mechanisms remain elusive.Objectives: The aim of the present study is to investigate the potential for CBD to modulate neurobiological, cognitive and psychological processes during anticipation of threatening stimuli.Methods: In a cross-over, double-blind, randomized trial, non-treatment seeking individuals diagnosed with AUD (DSM-V) were recruited to receive either 800mg of CBD or matched placebo, completing two respective fMRI sessions. Region of interest (ROI) and whole-brain analysis were utilized to examine treatment effects on neural activity in response to high vs low threat anticipation stimuli during a fear anticipation continuous performance task (FCPT).Results: Sixteen participants contributed complete FCPT data and fourteen contributed analysable fMRI data. No main treatment effects were observed across cognition, regional or whole-brain activation. Drinking the day before the scan was associated with longer latencies in responses on the continuous performance task.Conclusion: The present findings indicate that CBD did not produce measurable effects on brain activity or cognitive performance during threat anticipation in individuals with AUD suggesting that previously reported neural effects may be more closely related to direct responses to salient stimuli rather than anticipatory processes.","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00213-026-07148-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Rationale: Cannabidiol (CBD) has previously been suggested to be an emerging pharmacotherapy for Alcohol Use Disorder (AUD), however, results from clinical studies remain mixed and potential mechanisms remain elusive.

Objectives: The aim of the present study is to investigate the potential for CBD to modulate neurobiological, cognitive and psychological processes during anticipation of threatening stimuli.

Methods: In a cross-over, double-blind, randomized trial, non-treatment seeking individuals diagnosed with AUD (DSM-V) were recruited to receive either 800mg of CBD or matched placebo, completing two respective fMRI sessions. Region of interest (ROI) and whole-brain analysis were utilized to examine treatment effects on neural activity in response to high vs low threat anticipation stimuli during a fear anticipation continuous performance task (FCPT).

Results: Sixteen participants contributed complete FCPT data and fourteen contributed analysable fMRI data. No main treatment effects were observed across cognition, regional or whole-brain activation. Drinking the day before the scan was associated with longer latencies in responses on the continuous performance task.

Conclusion: The present findings indicate that CBD did not produce measurable effects on brain activity or cognitive performance during threat anticipation in individuals with AUD suggesting that previously reported neural effects may be more closely related to direct responses to salient stimuli rather than anticipatory processes.

查看原文本刊更多论文

大麻二酚与酒精使用障碍中威胁预期的神经相关性

理由：大麻二酚（CBD）之前被认为是一种新兴的药物治疗酒精使用障碍（AUD），然而，临床研究的结果仍然是混合的，潜在的机制仍然难以捉摸。目的：本研究的目的是研究CBD在预期威胁刺激时调节神经生物学、认知和心理过程的潜力。方法：在一项交叉、双盲、随机试验中，招募了诊断为AUD （DSM-V）的非寻求治疗的个体，接受800mg CBD或匹配的安慰剂，完成两个各自的功能磁共振成像疗程。利用感兴趣区域（ROI）和全脑分析来研究在恐惧预期连续表现任务（FCPT）中，高威胁预期刺激和低威胁预期刺激对神经活动反应的治疗效果。结果：16名参与者提供了完整的FCPT数据，14名参与者提供了可分析的fMRI数据。在认知、区域或全脑激活方面没有观察到主要的治疗效果。在扫描前一天喝酒与连续性能任务的反应延迟较长有关。结论：目前的研究结果表明，CBD对AUD患者在威胁预期期间的大脑活动或认知表现没有产生可测量的影响，这表明先前报道的神经效应可能与对显著刺激的直接反应更密切相关，而不是预期过程。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Psychopharmacology 医学-精神病学

CiteScore

7.10

自引率

5.90%

发文量

257

审稿时长

2-4 weeks

期刊介绍： Official Journal of the European Behavioural Pharmacology Society (EBPS) Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields: Human Psychopharmacology: Experimental This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered. Human Psychopharmacology: Clinical and Translational This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects. Preclinical psychopharmacology: Behavioral and Neural This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels. Preclinical Psychopharmacology: Translational This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways. Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.